Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17150526 | 0.81 | BCAT2 (0.38) | BCAT2 | |
| SCHEMBL5302622 | 0.77 | KCNJ1 (0.43) | LMNANNMTBCAT2 | |
| SCHEMBL26828742 | 0.74 | APLNR (0.35) | — | |
| SCHEMBL9924106 | 0.73 | JUN (0.37) | LMNA | |
| SCHEMBL28877834 | 0.72 | CYP1A2 (0.33) | LMNA | |
| SCHEMBL17814823 | 0.71 | — | — | |
| SCHEMBL31490392 | 0.71 | — | — | |
| SCHEMBL1255843 | 0.71 | — | — | |
| SCHEMBL2177672 | 0.70 | GABRP (0.43) | LMNANNMTBCAT2 | |
| SCHEMBL21936458 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220259198-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-114072390-A | RAD51 inhibitors | 赛泰尔治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3938358-A1 | RAD51 INHIBITORS | Cyteir Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2020186006-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020186006-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247988-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | LMNA 2555/4885NNMT 1638/4885BCAT2 3454/4885 |
| US-20220259198-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | LMNA 2555/4885NNMT 1638/4885BCAT2 3454/4885 |
| US-20200291014-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | LMNA 2555/4885NNMT 1638/4885BCAT2 3454/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | LMNA 2555/4885NNMT 1638/4885BCAT2 3454/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | LMNA 2555/4885NNMT 1638/4885BCAT2 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.